Group 1 - The company announced the resignation of key executives, including Wang Aiping, Cao Heling, and Cao Jianan, due to governance structure adjustments following the revision of the Company Law [3] - Wang Aiping and Cao Heling both resigned from their positions as directors and vice chairpersons, while Cao Jianan stepped down as the chairman of the supervisory board [3] - The revenue composition for the company in 2024 is projected to be 97.87% from the medical industry, 2.07% from other social services, 0.04% from software and information technology services, and 0.02% from commodity circulation [1]

（文章来源：每日经济新闻） 国际医学（SZ 000516，收盘价：5.46元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收入 约20.34亿元，同比减少15.95%；归属于上市公司股东的净利润亏损约1.65亿元；基本每股收益亏损 0.073元。2024年同期营业收入约24.2亿元；归属于上市公司股东的净利润亏损约1.74亿元；基本每股收 益亏损0.0768元。 ...

西安国际医学投资股份有限公司 2025 年半年度财务报告 （未经审计） 2025 年 8 月 20 日 西安国际医学投资股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 | 编制单位：西安国际医学投资股份有限公司 | 2025 年 06 月 30 日（未经审计） | 单位：元 | | --- | --- | --- | | 项目 | 期末余额 | 期初余额 | | 流动资产： | | | | 货币资金 | 397,812,399.82 | 590,562,003.38 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 15,335,398.00 | 89,074,177.50 | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 594,164,437.89 | 739,394,118.00 | | 应收款项融资 | | | | 预付款项 | 18,838,552.95 | 14,918,233.92 | | 应收保费 | ...

证券代码：000516 证券简称：国际医学 公告编号：2025-038 西安国际医学投资股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开的基本情况 1.股东会届次：本次股东会是 2025 年第一次临时股东会。 2.召集人：西安国际医学投资股份有限公司董事会。 3.公司第十三届董事会第六次会议审议通过了关于召开公司 2025 年第一次 临时股东会的事项。会议的召开符合《公司法》《上市公司股东会规则》《股 票上市规则》等有关法律法规、规范性文件的规定和《公司章程》的要求。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 9 月 8 日的交易时间，即 09:15—09:25，09:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为：2025 年 9 月 8 日 09:15—15:00 期间任意时间。 5.会议的召开方式：现场表决和网络投票相结合的方式。 公司将通过深圳证券交易所交易系统和互联网投票系统向全体股东提供网络 形式的投票平 ...

西安国际医学投资股份有限公司董事会于2025年8月11日以书面 方式发出召开公司第十三届董事会第六次会议的通知，并于2025年8 月20日在公司总部会议室以现场表决形式召开。会议应到董事7人， 实到董事7人，出席会议的董事有史今、刘旭、刘瑞轩、孙文国、师 萍、张宝通、李成，公司监事会成员列席了会议。会议的召开符合有 关法律、法规、规章和《公司章程》的规定。会议由史今董事长主持。 经会议认真审议和投票表决，通过了下述决议： 一、通过公司《2025 年半年度报告》及其摘要（7 票同意、0 票 反对、0 票弃权）； 二、通过《关于修改<公司章程>的议案》（7 票同意、0 票反对、 0 票弃权）； 为了进一步提高公司治理水平，根据《中华人民共和国公司法》、 中国证券监督管理委员会《上市公司章程指引》《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、行政法规、部门规章和规范性文件的 相关规定，结合公司的实际情况，同意对《公司章程》进行修改。 证券代码：000516 证券简称：国际医学 公告编号：2025-035 西安国际医学投资股份有限公司 第十三届董事会 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥2,034,307,690.46, a decrease of 15.95% compared to ¥2,420,461,714.17 in the same period last year[21]. - The net loss attributable to shareholders was ¥164,961,830.49, showing an improvement of 4.98% from a loss of ¥173,605,843.66 in the previous year[21]. - The net cash flow from operating activities increased by 12.75% to ¥592,541,964.05, compared to ¥525,513,894.06 in the same period last year[21]. - The total assets at the end of the reporting period were ¥10,005,511,672.12, a decrease of 5.93% from ¥10,636,321,992.89 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 5.68% to ¥3,466,264,833.36 from ¥3,674,927,755.19 at the end of the previous year[21]. - The company reported a basic and diluted earnings per share of -¥0.0730, an improvement of 4.95% from -¥0.0768 in the same period last year[21]. - The company's revenue for the first half of 2025 was 2,034.31 million yuan, a decrease of 15.95% compared to the same period last year, with a net profit attributable to shareholders of the listed company at -164.96 million yuan, a reduction in loss of 4.98% year-on-year[31]. - The company achieved a net operating cash flow of 592.54 million yuan, an increase of 12.75% year-on-year, indicating improved operational efficiency[31]. Operational Developments - The company focuses on high-quality healthcare services and aims to enhance grassroots health service levels while promoting the integration of medical and elderly care[28]. - The company is committed to providing high-quality, diverse healthcare services to meet the varied health needs of the public[28]. - The company emphasizes differentiated operational strategies and internal management optimization to improve efficiency[28]. - In the first half of 2025, the company provided a total of 1.3191 million outpatient and emergency services, an increase of 5.42% year-on-year, while inpatient services decreased by 4.01% to 96,300 cases[31]. - The West High-tech Hospital reported an outpatient and emergency service volume of 578,700 cases, a growth of 3.04% year-on-year, while inpatient services decreased by 6.48% to 30,300 cases[37]. - The company established 5 new specialty treatment centers and 7 new specialty outpatient clinics in the first half of 2025, enhancing its service offerings to meet diverse patient needs[38]. - The hospital completed 612 clinical applications of restricted technologies, including 66 at the national level, demonstrating significant advancements in clinical capabilities[39]. - The company was awarded 9 new research projects during the reporting period, with 22 academic papers published, 6 of which were included in SCI journals, reflecting its commitment to academic excellence[40]. - The company successfully implemented 13 continuing education projects at various levels, supporting talent development in the healthcare sector[41]. - The hospital introduced a "one-stop" medical insurance settlement window, significantly improving the efficiency of the settlement process for patients[42]. Strategic Initiatives - The company has established a total of 145 cooperative medical institutions, including 18 tertiary hospitals, 69 secondary hospitals, and 58 community health centers, promoting the downward flow of quality medical resources[56]. - The company is constructing a proton therapy center, which will be the sixth in the country and the first in Northwest China, marking a significant advancement in cancer radiation treatment[65]. - The company has implemented a monthly special data verification and dynamic monitoring mechanism to improve operational management quality and efficiency, successfully passing the data verification by the Shaanxi Provincial Health Commission[55]. - The company has organized 72 free medical activities, benefiting over 12,000 people, and provided free ultrasound screening services to more than 620 individuals[56]. - The company has optimized its operational model by integrating two hospital districts and enhancing personnel and compensation performance schemes to strengthen cost control while improving medical technology[55]. - The company is actively pursuing digital transformation in healthcare services, focusing on the integration of online and offline medical services to enhance patient experience and operational efficiency[67]. - The company has developed a diverse range of specialized departments, including cardiology, oncology, and reproductive medicine, to meet the varied healthcare needs of the population[65]. - The company has established a collaborative innovation network with top medical institutions and universities to enhance research and development capabilities and improve service quality[68]. Market Trends and Projections - By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, accounting for 22.0% of the total population, with projections indicating that this will exceed 400 million by 2035[70]. - The per capita healthcare expenditure in 2024 is projected to be 2,547 yuan, representing a year-on-year growth of 3.6% and accounting for 9.0% of per capita consumption expenditure[70]. - The "silver economy" market size in China is expected to exceed 9 trillion yuan by 2025, with an annual compound growth rate of over 15%, and is projected to reach 30 trillion yuan by 2035, accounting for approximately 10% of GDP[71]. - The implementation of the DRG/DIP 2.0 payment model in 2025 will shift the payment system from fee-for-service to a fixed payment per diagnosis, promoting efficiency and quality in healthcare services[75]. - The company is well-positioned to leverage the ongoing healthcare reforms and demographic trends, creating significant growth opportunities in the evolving healthcare landscape[76]. Shareholder and Governance Matters - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[114]. - The company has implemented a restricted stock incentive plan, granting 7,469,601 shares to 115 core technical and management personnel[115]. - The company faces risks related to medical policy changes, market competition, management operations, and human resource shortages[105][106][107][108]. - Major subsidiaries include Xi'an High-tech Hospital with total assets of ¥2,083,522,000 and Xi'an International Medical Center with total assets of ¥4,978,786,000[103][104]. - The company has cultivated a strong team of medical professionals, including experts from renowned institutions, ensuring high-quality medical services and a solid foundation for long-term growth[80]. - The company has actively engaged in social responsibility, focusing on protecting the rights of shareholders, creditors, employees, suppliers, and patients[121]. - The company emphasizes environmental protection and sustainable development, promoting low-carbon and energy-saving practices among employees[125]. Financial Management and Risks - The company has established a value management system in August 2025 to enhance its market value management capabilities[110]. - The company has no ongoing or completed leasing projects that contributed over 10% to the total profit for the reporting period[146]. - The company did not engage in any violations regarding external guarantees during the reporting period[129]. - The company did not experience any penalties or rectification situations during the reporting period[134]. - The company did not have any trust, contracting, or leasing situations during the reporting period[143]. - The total amount of external guarantees approved during the reporting period was 0[148]. - The company has no significant contracts during the reporting period[160]. - The company has no high-risk entrusted financial management situations that may lead to impairment[160].

《股东会议事规则》修订对照表 西安国际医学投资股份有限公司 （第十三届董事会第六次会议修订通过） 2025 年 8 月 20 日，西安国际医学投资股份有限公司（以下简称"公 司"）第十三届董事会第六次会议审议通过了《关于修改<股东会议事规 则> 的议案》，根据《中华人民共和国公司法》、中国证券监督管理委 员会《上市公司章程指引（2025 年修订）》《上市公司股东会规则（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作（2025 年修订）》等法律、行政法规、部门规章和规范 性文件及《西安国际医学投资股份有限公司章程》（以下简称：公司章 程）的有关规定，结合公司的实际情况，拟对《股东会议事规则》中的 部分条款进行修订，具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为了规范股东大会议 | 第一条 为了规范股东会议事和决策程序， | | 事和决策程序，保证公司股东大会依 | 保证公司股东会依法行使职权，保护公司和股东 | | 法行使职权，保护公司和股东的合法 | 的合法权益，保障公司所有股东公 ...

西安国际医学投资股份有限公司 独立董事工作细则 （第十三届董事会第六次会议修订通过） 第一章 总则 第一条 为进一步完善西安国际医学投资股份有限公司（以下简 称"公司"）治理结构，促进公司规范运作，规范独立董事行为，充 分发挥独立董事在公司治理的作用，明确独立董事的职责权限，保证 独立董事依法行使职权，根据《中华人民共和国公司法》（以下简称 《公司法》）《上市公司治理准则》《上市公司独立董事管理办法》等 法律、法规、规范性文件以及《西安国际医学投资股份有限公司章程》 （以下简称"公司章程"）的有关规定，制定本工作细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制 人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 按照法律、行政法规、中国证券监督管理委员会（以下简称"中国证 监会"）规定、深圳证券交易所业务规则和公司章程的规定，认真履 行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护 公司整 ...

西安国际医学投资股份有限公司 《董事会议事规则》修订对照表 2025 年 8 月 20 日，西安国际医学投资股份有限公司（以下简称 "公司"）第十三届董事会第六次会议审议通过了《关于修改<董事 会议事规则> 的议案》，根据《中华人民共和国公司法》、中国证券 监督管理委员会《上市公司章程指引（2025 年修订）》《深圳证券交 易所股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作（2025 年修订）》等法律、 行政法规、部门规章和规范性文件及《西安国际医学投资股份有限公 司章程》（以下简称：公司章程）的有关规定，结合公司的实际情况， 拟对《董事会议事规则》中的部分条款进行修订，具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为规范董事会议事程序，提高 | 本条无变化 | | 董事会工作效率和决策水平，根据《中华 | | | 人民共和国公司法》《中华人民共和国证 | | | 券法》《上市公司治理准则》《深圳证券 | | | 交易所股票上市规则》（以下简称《股票 | | | 上市规 ...

西安国际医学投资股份有限公司 董事会专门委员会工作细则 （第十三届董事会第六次会议修订通过） 董事会战略决策委员会工作细则 第一章 总 则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定 公司发展规划，健全投资决策程序，加强决策科学性，提高重大投资 决策的效益和决策的质量，完善公司治理结构，根据《中华人民共和 国公司法》《上市公司治理准则》《上市公司独立董事管理办法》《公 司章程》及其他有关规定，公司特设立董事会战略决策委员会，并制 定本工作细则。 第二条 董事会战略决策委员会是董事会按照股东会决议设立的 专门工作机构，主要负责对公司长期发展战略和投资决策进行研究并 提出建议。 第二章 人员组成 第三条 战略决策委员会成员由五名董事组成，其中包括公司董 事长和至少一名独立董事。 第四条 战略决策委员会委员由董事长、二分之一以上独立董事 或者全体董事的三分之一提名，并由董事会选举产生。 第五条 战略决策委员会设主任委员（召集人）一名，由公司董 事长担任。 1 第六条 战略委员会任期与董事会任期一致，委员任期届满，可 以连选连任。 期间如有委员不再担任公司董事职务，自动失去委员 资格，董事会应根据《公司 ...